Quinolone use in the developing world: state of the art.
The development of bacterial resistance to previously recommended standard therapy for common childhood infections in developing countries, notably dysentery and invasive salmonellosis, has left treatment options limited to the quinolones. A number of randomised controlled trials of the quinolones in shigellosis have demonstrated their efficacy and safety in children. Strategies to make these drugs available in developing countries for specific indications should be devised. Quinolones, however, should be limited to specific indications in order to prevent the emergence of bacterial resistance and thus preserve their clinical efficacy for important childhood infectious diseases in developing countries.
Tupasi
T E
TE
Tropical Disease Foundation, Makati Medical Center, Makati City, The Philippines.
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D003906:Developing Countries; D003967:Diarrhea / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D004363:Drug Utilization; D004405:Dysentery, Bacillary / Q000188:drug therapy; D024841:Fluoroquinolones; D006801:Humans
D000890:Anti-Infective Agents; D024841:Fluoroquinolones